Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | STAMBP | O95630 | 1/20 | 0.41 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843241 | 0.93 | ATM (0.40) | L3MBTL1ATMMEN1KMT2AMET | |
| SCHEMBL836953 | 0.90 | MEN1 (0.41) | L3MBTL1ATMMEN1KMT2AMET | |
| SCHEMBL1952994 | 0.86 | PSMD14 (0.43) | L3MBTL1ATMMEN1KMT2ANAMPT | |
| SCHEMBL20406897 | 0.85 | MET (0.47) | MET | |
| SCHEMBL1953280 | 0.84 | PSMD14 (0.48) | MEN1KMT2ANAMPTPSMD14STAMBP | |
| SCHEMBL1953683 | 0.84 | MET (0.42) | METHPGDRAB9A | |
| SCHEMBL1951507 | 0.84 | RIPK1 (0.44) | MET | |
| SCHEMBL1954414 | 0.83 | ATR (0.42) | MET | |
| SCHEMBL1954362 | 0.82 | MET (0.45) | L3MBTL1MEN1KMT2AMETNAMPT | |
| SCHEMBL20406814 | 0.82 | MET (0.45) | METNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | claimed |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE HOLDINGS CORPORATION | 2020-10-08 | — | — | US | claimed |
| EP-3443958-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Holdings Corporation (US) | 2019-02-20 | — | — | EP | claimed |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2018-10-04 | — | — | US | claimed |
| US-20130324515-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-12-05 | — | — | US | claimed |
| EP-2099447-B1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORP (US) | 2012-11-07 | — | — | EP | claimed |
| EP-2497470-A1 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Incyte Corporation (US) | 2012-09-12 | — | — | EP | claimed |
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-06-09 | — | — | US | claimed |
| US-7767675-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-08-03 | — | — | US | claimed |
| EP-2099447-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Corporation (US) | 2009-09-16 | — | — | EP | claimed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | claimed |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | ERBB2, MERTK, ABL1 | L3MBTL1 2276/4885ATM 391/4885MEN1 947/4885 |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | L3MBTL1 2084/4885ATM 359/4885MEN1 863/4885 |
| US-20130324515-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | L3MBTL1 2276/4885ATM 391/4885MEN1 947/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | L3MBTL1 2276/4885ATM 391/4885MEN1 947/4885 |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | L3MBTL1 2084/4885ATM 359/4885MEN1 863/4885 |
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | L3MBTL1 2276/4885ATM 391/4885MEN1 947/4885 |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | ERBB2, MERTK, ABL1 | L3MBTL1 2276/4885ATM 391/4885MEN1 947/4885 |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | L3MBTL1 2276/4885ATM 391/4885MEN1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.